vs
Side-by-side financial comparison of BIOMERICA INC (BMRA) and Marathon Bancorp, Inc. (MBBC). Click either name above to swap in a different company.
Marathon Bancorp, Inc. is the larger business by last-quarter revenue ($2.2M vs $1.2M, roughly 1.9× BIOMERICA INC). Marathon Bancorp, Inc. runs the higher net margin — 22.3% vs -109.1%, a 131.4% gap on every dollar of revenue. On growth, Marathon Bancorp, Inc. posted the faster year-over-year revenue change (41.7% vs -26.0%). Over the past eight quarters, Marathon Bancorp, Inc.'s revenue compounded faster (20.3% CAGR vs -12.1%).
Biomerica Inc. is a global medical technology company that develops, manufactures and markets diagnostic test kits and related medical products. Its portfolio covers gastrointestinal conditions, infectious diseases, food intolerances and point-of-care testing solutions, serving clinical labs, healthcare providers and retail healthcare segments across North America, Europe and Asia.
Marathon Bancorp, Inc. is a Maryland-based financial holding company that primarily operates through its community bank subsidiary. It offers a full range of retail and commercial banking products including deposit accounts, consumer loans, commercial mortgages, and small business financing, serving individual and small-to-medium enterprise customers across local markets in Maryland.
BMRA vs MBBC — Head-to-Head
Income Statement — Q2 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.2M | $2.2M |
| Net Profit | $-1.3M | $501.4K |
| Gross Margin | 4.2% | — |
| Operating Margin | -113.5% | 26.2% |
| Net Margin | -109.1% | 22.3% |
| Revenue YoY | -26.0% | 41.7% |
| Net Profit YoY | -38.9% | 880.7% |
| EPS (diluted) | $-0.45 | $0.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.2M | $2.2M | ||
| Q3 25 | $1.4M | $2.1M | ||
| Q2 25 | — | $1.9M | ||
| Q1 25 | $1.1M | $1.7M | ||
| Q4 24 | $1.6M | $1.6M | ||
| Q3 24 | $1.8M | $1.6M | ||
| Q2 24 | $1.1M | $1.6M | ||
| Q1 24 | $1.0M | $1.6M |
| Q4 25 | $-1.3M | $501.4K | ||
| Q3 25 | $2.0K | $444.3K | ||
| Q2 25 | — | $-332.0K | ||
| Q1 25 | $-1.2M | $148.4K | ||
| Q4 24 | $-950.0K | $51.1K | ||
| Q3 24 | $-1.3M | $174.9K | ||
| Q2 24 | $-1.4M | $85.8K | ||
| Q1 24 | $-1.9M | $-631.1K |
| Q4 25 | 4.2% | — | ||
| Q3 25 | 30.7% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.7% | — | ||
| Q4 24 | 26.7% | — | ||
| Q3 24 | 16.0% | — | ||
| Q2 24 | 2.1% | — | ||
| Q1 24 | -14.7% | — |
| Q4 25 | -113.5% | 26.2% | ||
| Q3 25 | -81.0% | 25.5% | ||
| Q2 25 | — | -25.7% | ||
| Q1 25 | -108.1% | 11.6% | ||
| Q4 24 | -60.7% | 3.3% | ||
| Q3 24 | -75.7% | 13.4% | ||
| Q2 24 | -136.6% | 4.1% | ||
| Q1 24 | -196.7% | -53.7% |
| Q4 25 | -109.1% | 22.3% | ||
| Q3 25 | 0.1% | 20.7% | ||
| Q2 25 | — | -18.9% | ||
| Q1 25 | -103.9% | 8.9% | ||
| Q4 24 | -58.1% | 3.2% | ||
| Q3 24 | -72.8% | 10.8% | ||
| Q2 24 | -127.1% | 6.2% | ||
| Q1 24 | -188.6% | -40.7% |
| Q4 25 | $-0.45 | $0.19 | ||
| Q3 25 | $0.00 | $0.17 | ||
| Q2 25 | — | $-0.13 | ||
| Q1 25 | $-0.48 | $0.07 | ||
| Q4 24 | $-0.06 | $0.02 | ||
| Q3 24 | $-0.63 | $0.06 | ||
| Q2 24 | $-2.57 | $0.07 | ||
| Q1 24 | $-0.11 | $-0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.5M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $4.4M | $46.9M |
| Total Assets | $6.0M | $248.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.5M | — | ||
| Q3 25 | $3.1M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $3.1M | — | ||
| Q4 24 | $2.4M | — | ||
| Q3 24 | $2.8M | — | ||
| Q2 24 | $4.2M | — | ||
| Q1 24 | $5.3M | — |
| Q4 25 | $4.4M | $46.9M | ||
| Q3 25 | $5.2M | $46.3M | ||
| Q2 25 | — | $45.7M | ||
| Q1 25 | $5.5M | $32.0M | ||
| Q4 24 | $5.1M | $31.7M | ||
| Q3 24 | $5.3M | $31.6M | ||
| Q2 24 | $6.6M | $31.3M | ||
| Q1 24 | $7.8M | $31.4M |
| Q4 25 | $6.0M | $248.0M | ||
| Q3 25 | $6.9M | $246.0M | ||
| Q2 25 | — | $238.8M | ||
| Q1 25 | $7.4M | $236.8M | ||
| Q4 24 | $7.3M | $217.9M | ||
| Q3 24 | $7.9M | $216.5M | ||
| Q2 24 | $9.3M | $219.3M | ||
| Q1 24 | $10.3M | $225.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-991.0K | $1.4M |
| Free Cash FlowOCF − Capex | — | $1.4M |
| FCF MarginFCF / Revenue | — | 62.3% |
| Capex IntensityCapex / Revenue | — | 0.6% |
| Cash ConversionOCF / Net Profit | — | 2.82× |
| TTM Free Cash FlowTrailing 4 quarters | — | $3.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-991.0K | $1.4M | ||
| Q3 25 | $-268.0K | $464.0K | ||
| Q2 25 | — | $1.4M | ||
| Q1 25 | $-1.0M | $849.0K | ||
| Q4 24 | $-791.0K | $113.6K | ||
| Q3 24 | $-1.3M | $945.2K | ||
| Q2 24 | $-1.0M | $416.6K | ||
| Q1 24 | $-1.8M | $-802.1K |
| Q4 25 | — | $1.4M | ||
| Q3 25 | — | $456.6K | ||
| Q2 25 | — | $1.3M | ||
| Q1 25 | — | $773.2K | ||
| Q4 24 | — | $105.0K | ||
| Q3 24 | — | $921.6K | ||
| Q2 24 | $-1.1M | $-1.8M | ||
| Q1 24 | — | $-1.1M |
| Q4 25 | — | 62.3% | ||
| Q3 25 | — | 21.3% | ||
| Q2 25 | — | 66.0% | ||
| Q1 25 | — | 46.3% | ||
| Q4 24 | — | 6.6% | ||
| Q3 24 | — | 57.1% | ||
| Q2 24 | -95.5% | -118.5% | ||
| Q1 24 | — | -67.9% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | — | 0.3% | ||
| Q2 25 | — | 9.3% | ||
| Q1 25 | — | 4.5% | ||
| Q4 24 | — | 0.5% | ||
| Q3 24 | — | 1.5% | ||
| Q2 24 | 2.1% | 145.2% | ||
| Q1 24 | 0.0% | 16.2% |
| Q4 25 | — | 2.82× | ||
| Q3 25 | -134.00× | 1.04× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.72× | ||
| Q4 24 | — | 2.22× | ||
| Q3 24 | — | 5.40× | ||
| Q2 24 | — | 4.85× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
